Barclays
BLCM

Barclays’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Barclays’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-7
Closed – – 6584
2019
Q4 		$0 Sell
7
-9
-56% -$83 ﹤0.01% 6972
2019
Q3 		$0 Sell
16
-8,598
-100% -$112K ﹤0.01% 7271
2019
Q2 		$146K Buy
8,614
+7,449
+639% +$202K ﹤0.01% 5383
2019
Q1 		$39K Buy
1,165
+1,159
+19,317% +$38.7K ﹤0.01% 6050
2018
Q4 		$0 Sell
6
-3,509
-100% -$156K ﹤0.01% 7484
2018
Q3 		$216K Buy
3,515
+574
+20% +$38.9K ﹤0.01% 4942
2018
Q2 		$217K Buy
2,941
+1,621
+123% +$126K ﹤0.01% 4649
2018
Q1 		$86K Sell
1,320
-755
-36% -$57K ﹤0.01% 5491
2017
Q4 		$174K Sell
2,075
-2,853
-58% -$280K ﹤0.01% 4797
2017
Q3 		$569K Buy
4,928
+4,084
+484% +$430K ﹤0.01% 3493
2017
Q2 		$99K Sell
844
-744
-47% -$92.3K ﹤0.01% 4920
2017
Q1 		$196K Buy
1,588
+341
+27% +$44.7K ﹤0.01% 4347
2016
Q4 		$170K Buy
1,247
+1,225
+5,568% +$217K ﹤0.01% 4345
2016
Q3 		$4K Sell
22
-579
-96% -$99.7K ﹤0.01% 6092
2016
Q2 		$78K Buy
601
+583
+3,239% +$64.9K ﹤0.01% 4567
2016
Q1 		$2K Sell
18
-30
-63% -$3.27K ﹤0.01% 5905
2015
Q4 		$9K Buy
48
+44
+1,100% +$7.87K ﹤0.01% 5440
2015
Q3 		$1K Sell
4
-12
-75% -$2.2K ﹤0.01% 6640
2015
Q2 		$3K Buy
16
+5
+45% +$1.23K ﹤0.01% 6717
2015
Q1 		$3K Buy
+11
New +$2.66K ﹤0.01% 6788

Other funds holding BLCM

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Barclays's BLCM Position: Q1 2020 in Review

Barclays sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q1 2020, closing a stake of 7 shares.

Barclays first reported a position in BLCM in Q1 2015 and held it in 20 quarters. The position peaked at $569K in Q3 2017. 29 funds tracked by Wall St. Rank hold BLCM as of Q1 2020.

  • Barclays reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
  • Barclays sold 7 Bellicum Pharmaceuticals, Inc. shares in Q1 2020.
  • Barclays first reported a position in Bellicum Pharmaceuticals, Inc. in Q1 2015 and held it in 20 quarters.
  • Barclays's Bellicum Pharmaceuticals, Inc. position peaked at $569K in Q3 2017.
  • 29 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q1 2020.

Based on Barclays's 13F filing for Q1 2020, filed 13 May 2020.